NCT01933945View on ClinicalTrials.gov

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib

CompletedOBSERVATIONAL
Enrollment

1,676

Participants

Timeline

Start Date

October 28, 2013

Primary Completion Date

July 22, 2017

Study Completion Date

November 10, 2017

Conditions
Carcinoma, Hepatocellular
Interventions
PROCEDURE

TACE (transarterial chemoembolization)

First treatment for all patients included in the study

DRUG

Sorafenib (Nexavar, BAY43-9006)

Trial Locations (31)

Unknown

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01933945 - Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib | Biotech Hunter | Biotech Hunter